ICAM1 and interstitial lung disease: In our cohort, ICAM1 + EVs were found to be linked with well-recognised risk factors of ILD progression and mortality, including dSSc, shorter disease duration, active disease, and FVC% decline, further supporting their role in PF-ILD (44, 45).